| Biomarker ID | 873 |
| PMID | 22355332 |
| Year | 2012 |
| Biomarker | cDNA FLJ51403 ; Elongation Factor 1A (EF-A1) ; Alpha 1B - glycoprotien; Complement component C7; Inter-alpha (Globulin) inhibitor H4; Kininogen 1; Plasma retinol-binding protien; cDNA FLJ77744; Complement C1r subcomponent-like Protein; Ficolin-3 |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Upregulated: [cDNA FLJ51403 (1.9 fold); Elongation Factor 1A (EF-A1) (1.8 fold); Alpha 1B - glycoprotien (1.1 fold) ; Complement component C7 (1.1 fold) ; Inter-alpha (Globulin) inhibitor H4;(1.1 fold)]; Downregulated: [Kininogen 1 (1.1 fold); Plasma retinol-binding protien (1.2 fold); cDNA FLJ77744 (1.4 fold); Complement C1r subcomponent-like Protein (1.4 fold); Ficolin-3 (1.4 fold)] |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Non Progressing Vs Progressing Prostate Cancer |
| Type of Biomarker | Prognostic |
| Cohort | Samples were collected from 4 groups with 5 samples each:benign prostatic hyperplasia (BPH); ii) localised cancer with no evidence of progression, (non-progressing) (iii) localised cancer with evidence of biochemical progression, (progressin), and (iv) bone metastasis at presentation (metastatic). |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p ≤0.01 |
| Method Used | 4-plex iTRAQ |
| Clinical | No |
| Remarks | represents biomarkers assessed individualy, + represents biomarkers assessed as a pair or panel |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | EEF1A1, A1BG, C7, ITIH4, KNG1, RBP1, C1RL, FCN3 |